China Pioneer Pharma Holdings Limited
Simbolis: 1345.HK
HKSE
1.42
HKDRinkos kaina šiandien
13.7445
P/E santykis
0.0000
PEG koeficientas
1.67B
MRK kapitalizacija
- 0.04%
DIV pajamingumas
China Pioneer Pharma Holdings Limited (1345-HK) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 0 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 0 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 0 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 0 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | -40.4 | -176.4 | -210.8 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | 0 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | 0 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 19 | 225.4 | 39.4 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 0 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 0 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 0 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 0 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 0 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 0 | 145.7 | 235.3 | 142.6 |
Dažnai užduodami klausimai
Kas yra China Pioneer Pharma Holdings Limited (1345.HK) bendras turtas?
China Pioneer Pharma Holdings Limited (1345.HK) bendras turtas yra 1530905000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.427.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.127.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.093.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.085.
Kas yra China Pioneer Pharma Holdings Limited (1345.HK) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 145718000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 74020000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 488030000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.